Celcuity (CELC) Stock Price, News & Analysis

Company Overview

Celcuity, Inc. (NASDAQ: CELC) is a clinical-stage biotechnology company focused on precision oncology for women’s cancers. The company applies its proprietary signal transduction profiling platform to identify critical aberrations in tumor cell pathways, enabling the development of targeted therapeutic candidates alongside companion diagnostics. By matching patients to therapies most likely to yield a response, Celcuity aims to improve clinical outcomes and reduce unnecessary exposure to ineffective treatments.

At the core of Celcuity’s pipeline is OvaRex, a first-in-class immunotherapy designed to engage specific cell surface receptors expressed in ovarian cancer. OvaRex is being evaluated in early-stage clinical trials, supported by a companion diagnostic assay that stratifies patients based on tumor biomarker signatures. This dual approach underscores the company’s strategy of integrating therapeutic and diagnostic innovation to advance precision medicine in gynecologic oncology.

Founded in 2013 and headquartered in La Jolla, California, Celcuity completed its initial public offering in 2018 and has since expanded its development activities across the United States and Europe. The company collaborates with leading academic and clinical research centers to conduct translational studies and early-phase trials. Celcuity’s research and manufacturing operations are supported by strategic partnerships that bolster its capabilities in assay development, biomanufacturing, and regulatory support.

Celcuity is led by a management team with extensive experience in oncology drug development, diagnostic innovation and commercialization. The executive leadership includes a chief executive officer with more than two decades in life-science strategy and operations, alongside a senior scientific team that has originated multiple investigational therapies from concept through clinical proof-of-concept. This seasoned leadership cadre positions Celcuity to advance its precision oncology platform toward value-driving milestones and future regulatory filings.

Key Stats

• Today's Range: $13.37 to $13.73
• 50-Day Range: $10.12 to $13.79
• 52-Week Range: $7.57 to $19.77
• Volume: 18,680 shs
• Average Volume: 240,955 shs
• Market Capitalization: $512.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.40
• Consensus Rating: Buy

Celcuity Stock Analysis - MarketRank™

Celcuity scored higher than 42% of companies evaluated by MarketBeat, and ranked 616th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Celcuity has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Celcuity has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Celcuity are expected to decrease in the coming year, from ($2.62) to ($3.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Celcuity is -4.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Celcuity is -4.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Celcuity has a P/B Ratio of 4.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.65% of the float of Celcuity has been sold short.

Short Interest Ratio / Days to Cover

Celcuity has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Celcuity has recently decreased by 1.61%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Celcuity does not currently pay a dividend.

Dividend Growth

Celcuity does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.65% of the float of Celcuity has been sold short.

Short Interest Ratio / Days to Cover

Celcuity has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Celcuity has recently decreased by 1.61%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.24

News Sentiment

Celcuity has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Celcuity this week, compared to 3 articles on an average week.

MarketBeat Follows

2 people have added Celcuity to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Celcuity insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.78% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

63.33% of the stock of Celcuity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CELC Stock Analysis - Frequently Asked Questions

How have CELC shares performed this year?

Celcuity's stock was trading at $13.09 at the beginning of 2025. Since then, CELC stock has increased by 1.9% and is now trading at $13.34.

How were Celcuity's earnings last quarter?

Celcuity, Inc. (NASDAQ:CELC) released its earnings results on Wednesday, May, 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.95) by $0.09.
Read the conference call transcript.

When did Celcuity IPO?

Celcuity (CELC) raised $18 million in an IPO on Wednesday, September 20th 2017. The company issued 2,000,000 shares at a price of $8.00-$10.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

How do I buy shares of Celcuity?

Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Celcuity own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Celcuity investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/07/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:CELC
• CIK: 1603454
• Web: www.celcuity.com
• Phone: (763) 392-0767
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $28.40
• High Stock Price Target: $30.00
• Low Stock Price Target: $27.00
• Potential Upside/Downside: +112.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$111.78 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -96.21%
• Return on Assets: -49.44%

Debt

• Debt-to-Equity Ratio: 1.14
• Current Ratio: 6.61
• Quick Ratio: 6.61

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.11 per share
• Price / Book: 4.29

Miscellaneous

• Outstanding Shares: 37,870,000
• Free Float: 31,891,000
• Market Cap: $505.19 million
• Optionable: Optionable
• Beta: 0.45